OlaparibCapecitabinePercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)RadiationtherapyTamoxifenTDM-1(Ado-trastuzumabemtansine)TNBC1yearVenlafaxinePembrolizumabIntermediate(11-25)TC (docetaxel /cyclophosphamide)LoperamideprophylaxisAbemaciclib10yearsEverymonthTaxanesAromataseinhibitors2yearsExemestaneChemoendocrinetherapyAnthracyclinesLVEFmonitoringPertuzumabOlaparibCapecitabinePercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)RadiationtherapyTamoxifenTDM-1(Ado-trastuzumabemtansine)TNBC1yearVenlafaxinePembrolizumabIntermediate(11-25)TC (docetaxel /cyclophosphamide)LoperamideprophylaxisAbemaciclib10yearsEverymonthTaxanesAromataseinhibitors2yearsExemestaneChemoendocrinetherapyAnthracyclinesLVEFmonitoringPertuzumab

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Olaparib
  2. Capecitabine
  3. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  4. Radiation therapy
  5. Tamoxifen
  6. TDM-1 (Ado-trastuzumab emtansine)
  7. TNBC
  8. 1 year
  9. Venlafaxine
  10. Pembrolizumab
  11. Intermediate (11-25)
  12. TC (docetaxel / cyclophosphamide)
  13. Loperamide prophylaxis
  14. Abemaciclib
  15. 10 years
  16. Every month
  17. Taxanes
  18. Aromatase inhibitors
  19. 2 years
  20. Exemestane
  21. Chemoendocrine therapy
  22. Anthracyclines
  23. LVEF monitoring
  24. Pertuzumab